ABOS - Acumen Pharmaceuticals, Inc.

QQQ $ 439.59 $ 1.36 (0.31 %)

DIA $ 390.50 $ 1.77 (0.46 %)

SPY $ 517.10 $ -0.04 (-0.01 %)

TLT $ 90.18 $ -0.54 (-0.6 %)

GLD $ 213.58 $ -0.63 (-0.29 %)

Previous Close

$ 3.36

Open

$ 3.50

Bid

$ 3.39 x 100

Ask

$ 3.40 x 100

Day's Range

$ 3.39 - $ 3.52

52 Week Range

$ 1.81 - $ 11.31

Volume

140,223

Average Volume

Market Cap

163.33M

Beta (5Y Monthly)

$ 0.68

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	03-26-2024	12-31-2023	10-K
2	11-13-2023	09-30-2023	10-Q
3	08-08-2023	06-30-2023	10-Q
4	05-09-2023	03-31-2023	10-Q
5	03-27-2023	12-31-2022	10-K
6	11-14-2022	09-30-2022	10-Q
7	08-15-2022	06-30-2022	10-Q
8	05-16-2022	03-31-2022	10-Q
9	03-28-2022	12-31-2021	10-K
10	11-15-2021	09-30-2021	10-Q
11	08-16-2021	06-30-2021	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Acumen Pharmaceuticals Says First Patient ...
05/08/2024 12:28:21

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targ...

Watching Eledon Pharmaceuticals, Acumen Ph...
04/18/2024 15:41:59

https://blog.tipranks.com/these-2-strong-buy-penny-stocks-are-poised-for-over-300-gains-say-analysts/

Acumen Pharmaceuticals Presents First Comp...
04/16/2024 12:17:32

Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker change...

Acumen Pharmaceuticals Collaborates With L...
04/04/2024 12:03:36

HC Wainwright & Co. Maintains Buy on Acume...
03/27/2024 13:22:02

HC Wainwright & Co. analyst Andrew Fein maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $15 pric...

Acumen Pharmaceuticals Q4 EPS $(0.29) Miss...
03/26/2024 13:28:09

Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate...

Acumen Pharmaceuticals FY23 EPS $(1.08) Do...
03/26/2024 11:08:43

Earnings Scheduled For March 26, 2024
03/26/2024 08:47:27

Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on reve...

Acumen Pharmaceuticals's Earnings: A Preview
03/25/2024 15:02:18

Acumen Pharmaceuticals To Present Deeper I...
03/21/2024 12:07:54

- Company on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024 CHARLOTTESVILLE, Va., March 21, 2024 (...

Acumen Pharmaceuticals Presents Sabirnetug...
03/08/2024 13:57:48

Cerebrospinal fluid (CSF) biomarker results are highly supportive of sabirnetug's downstream pharmacological effects in the...

Acumen Pharmaceuticals shares are trading ...
03/08/2024 13:52:30

Acumen Pharmaceuticals To Present Sabirnet...
02/21/2024 13:24:53

- Oral presentation to explore drug effect of sabirnetug (ACU193) on key cerebrospinal fluid biomarkers in early AD- Poster...

Acumen Pharmaceuticals Appointsf James Doh...
02/01/2024 12:31:07

Deutsche Bank Initiates Coverage On Acumen...
12/12/2023 09:30:11

Deutsche Bank analyst Neena Bitritto-Garg initiates coverage on Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy rating and a...

Acumen Pharmaceuticals Secures $50.0M Cred...
11/13/2023 12:08:29

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical comp...

Acumen Pharmaceuticals Q3 EPS $(0.24) Vs $...
11/13/2023 12:04:27

Earnings Scheduled For November 13, 2023
11/13/2023 11:40:53

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr...

Acumen Pharmaceuticals's Earnings Outlook
11/10/2023 18:01:53

Acumen Pharmaceuticals, Inc. And Halozyme ...
11/06/2023 12:31:18